Decision: Favourable

Study Title:

A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis ADORE (ALS Deceleration with ORal Edaravone) study

  • NREC Code:

    21-NREC-CT-020

  • Decision:

    Favourable

  • Meeting Date:

    21/07/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Orla Hardiman

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Ferrer International S.A.

Scroll to Top